trial

A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

NCTId NCT07145918
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Recruiting
Enrollment 268 (estimated)
Sponsored by AbbVie
Primary completion 2028-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Recruiting
Enrollment
268 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Sequential
Masking
Quadruple
Start
2025-08-04
Primary completion
2028-02
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Emraclidine

Sponsors

AbbVieLead Sponsor

Sites

7 total
Little Rock, United StatesGarden Grove, United StatesGlendale, United StatesGaithersburg, United StatesMarlton, United StatesAustin, United StatesRichardson, United States

Linked catalysts

1
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emrac — primary completion2028-02

Facts & assertions

4 sourced
Enrollment
268
Phase
PHASE2
Primary Completion Date
2028-02
Status
RECRUITING
relationships
The graph out of here
drug
Emraclidine
drug
lead_sponsor
AbbVie
company
indication
Schizophrenia
indication
Schizophrenia
indication